ChemicalBook
Chinese English Japanese Germany Korea

4,4'-설포닐디아닐린

4,4'-설포닐디아닐린
4,4'-설포닐디아닐린 구조식 이미지
카스 번호:
80-08-0
한글명:
4,4'-설포닐디아닐린
동의어(한글):
댑손;4,4'-설포닐디아닐린;답손
상품명:
4,4'-Diaminodiphenylsulfone
동의어(영문):
DDS;K509;wr448;DADPS;1358F;f1358;DADDS;Udolac;WR 448;EPORAL
CBNumber:
CB0152851
분자식:
C12H12N2O2S
포뮬러 무게:
248.3
MOL 파일:
80-08-0.mol

4,4'-설포닐디아닐린 속성

녹는점
175-177 °C(lit.)
밀도
1.2701 (rough estimate)
굴절률
1.5950 (estimate)
저장 조건
-20°C Freezer
용해도
0.38g/l
물리적 상태
Crystalline Powder
산도 계수 (pKa)
pKb 13.0(at 25℃)
색상
White to beige
수소이온지수(pH)
5.5-7.5 (H2O, 20℃)(saturated aqueous solution)
수용성
<0.1 g/100 mL at 20 ºC
Merck
14,2822
BRN
788055
안정성
Stable. Combustible. Incompatible with strong oxidizing agents.
InChIKey
MQJKPEGWNLWLTK-UHFFFAOYSA-N
CAS 데이터베이스
80-08-0(CAS DataBase Reference)
NIST
Dapsone(80-08-0)
EPA
Benzenamine, 4,4'-sulfonylbis-(80-08-0)
안전
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
위험품 표기 Xn
위험 카페고리 넘버 22
안전지침서 22
유엔번호(UN No.) 3249
WGK 독일 1
RTECS 번호 BY8925000
TSCA Yes
위험 등급 6.1(b)
포장분류 III
HS 번호 29051620
HS 번호 29309070
유해 물질 데이터 80-08-0(Hazardous Substances Data)
독성 LD50 orally in Rabbit: 1000 mg/kg LD50 dermal Rabbit > 4000 mg/kg
그림문자(GHS):
신호 어: Warning
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H302 삼키면 유해함 급성 독성 물질 - 경구 구분 4 경고 P264, P270, P301+P312, P330, P501
H320 눈에 자극을 일으킴 심한 눈 손상 또는 자극성 물질 구분 2B 경고 P264, P305+P351+P338,P337+P313
H370 장기(또는, 영향을 받은 알려진 모든 장기를 명시)에 손상을 일으킴(노출되어도 특정 표적장기 독성을 일으키지 않는다는 결정적인 노출경로가 있다면 노출경로를 기재) 특정 표적장기 독성 - 1회 노출 구분 1 위험 P260, P264, P270, P307+P311, P321,P405, P501
H372 장기간 또는 반복 노출되면 장기(또는, 영향을 받은 알려진 모든 장기를 명시)에 손상을 일으킴 특정 표적장기 독성 - 반복 노출 구분 1 위험 P260, P264, P270, P314, P501
예방조치문구:
P260 분진·흄·가스·미스트·증기·...·스프레이를 흡입하지 마시오.
P261 분진·흄·가스·미스트·증기·...·스프레이의 흡입을 피하시오.
P264 취급 후에는 손을 철저히 씻으시오.
P264 취급 후에는 손을 철저히 씻으시오.
P270 이 제품을 사용할 때에는 먹거나, 마시거나 흡연하지 마시오.
P307+P311 노출된 경우,독성 물질 센터 또는 의사에게 전화하기
P405 밀봉하여 저장하시오.
P501 ...에 내용물 / 용기를 폐기 하시오.

4,4'-설포닐디아닐린 MSDS


Dapsonum

4,4'-설포닐디아닐린 C화학적 특성, 용도, 생산

화학적 성질

Off -White Crystalline Solid

용도

An antibacterial used in the treatment of dermatitis herpetiformis

용도

antibacterial, leprostatic, dermatitis herpetiformis suppressant

용도

4,4'-diaminodiphenylsulfone be used for preparation polyimide and epoxy resin material.

용도

Hardening agent in the curing of epoxy resins.

정의

ChEBI: A sulfone that is diphenylsulfone in which the hydrogen atom at the 4 position of each of the phenyl groups is substituted by an amino group. It is active against a wide range of bacteria, but is mainly employed for its actions against Mycobacteriu leprae, being used as part of multidrug regimens in the treatment of all forms of leprosy.

Indications

Although dapsone (Avlosulfon) is most often used as an antimicrobial agent, it has important antiinflammatory properties in many noninfectious skin diseases. The mechanism of action of dapsone in skin disease is not clear.Most of the cutaneous diseases for which it is effective manifest inflammation and are characterized by an infiltration of neutrophils; the drug’s antiinflammatory effect may arise from its inhibition of intracellular neutrophil reactions mediated by myeloperoxidase and hydrogen peroxide or from its scavenging of reactive oxygen species, which inhibits inflammation.

Indications

Although dapsone (Avlosulfon) was once used in the treatment and prophylaxis of chloroquine-resistant P. falciparum malaria, the toxicities associated with its administration (e.g., agranulocytosis, methemoglobinemia, hemolytic anemia) have severely reduced its use. Occasionally dapsone has been added to the usual chloroquine therapeutic regimen for the prophylaxis of chloroquine-resistant P. falciparum malaria. It is also used in combination therapy for leprosy.

상표명

Hansolar (ParkeDavis).

Antimicrobial activity

Dapsone is active against many bacteria and some protozoa. Fully susceptible strains of M. leprae are inhibited by a little as 0.003 mg/L. It is predominantly bacteristatic. Resistance is associated with mutations in the folP1 gene involved in the synthesis of para-aminobenzoic acid.

원료

Resistance to high levels is acquired by several sequential mutations. As a result of prolonged use of dapsone monotherapy, acquired resistance emerged in patients with multibacillary leprosy in many countries. Initial resistance also occurs in patients with both paucibacillary and multibacillary leprosy. Thus, leprosy should always be treated with multidrug regimens. Resistance of M. leprae to dapsone (and other anti-leprosy drugs) may now be determined by use of DNA microarrays.

일반 설명

Odorless white or creamy white crystalline powder. Slightly bitter taste.

공기와 물의 반응

Sensitive to oxidation and light. Insoluble in water.

반응 프로필

4,4'-Diaminodiphenylsulfone can neutralize acids in exothermic reactions to form salts plus water. May be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. Flammable gaseous hydrogen is generated in combination with strong reducing agents, such as hydrides. Incompatible with strong oxidizing agents. Also incompatible with epoxy resins under uncontrolled conditions .

화재위험

4,4'-Diaminodiphenylsulfone is probably combustible.

Pharmaceutical Applications

The most effective of a number of sulfonamide derivatives to be tested against leprosy. The dry powder is very stable. It is only slightly soluble in water.

Pharmacokinetics

Oral absorption: >90%
Cmax 100 mg oral: c. 2 mg/L after 3–6 h
Plasma half-life: 10–50 h
Plasma protein binding: c. 50%
It is slowly but almost completely absorbed from the intestine and widely distributed in the tissues, but selectively retained in skin, muscle, kidneys and liver. It is metabolized by N-oxidation and also by acetylation, which is subject to the same genetic polymorphism as isoniazid. The elimination half-life is consequently very variable, but on standard therapy the trough levels are always well in excess of inhibitory concentrations. It is mostly excreted in the urine: in the unchanged form (20%), as N-oxidation products (30%) and as a range of other metabolites.

Clinical Use

Dapsone (4,4 -sulfonylbisbenzeneamine; 4,4 -sulfonyldianiline;p,p -diaminodiphenylsulfone; or DDS [Avlosulfon])occurs as an odorless, white crystalline powder that is veryslightly soluble in water and sparingly soluble in alcohol.The pure compound is light stable, but traces of impurities,including water, make it photosensitive and thus susceptibleto discoloration in light. Although no chemical change is detectablefollowing discoloration, the drug should be protectedfrom light.
Dapsone is used in the treatment of both lepromatous andtuberculoid types of leprosy. Dapsone is used widely for allforms of leprosy, often in combination with clofazimine andrifampin. Initial treatment often includes rifampin with dapsone,followed by dapsone alone. It is also used to preventthe occurrence of multibacillary leprosy when given prophylactically.Dapsone is also the drug of choice for dermatitis herpetiformisand is sometimes used with pyrimethamine for treatmentof malaria and with trimethoprim for PCP.
Serious side effects can include hemolytic anemia,methemoglobinemia, and toxic hepatic effects. Hemolyticeffects can be pronounced in patients with glucose-6-phosphatedehydrogenase deficiency. During therapy, all patientsrequire frequent blood counts.

Clinical Use

Dapsone is approved for the treatment of an autoimmune blistering skin disease, dermatitis herpetiformis. This intensely pruritic eruption is characterized histologically by a dense dermal infiltration of neutrophils and subepidermal blisters. Other skin diseases in which dapsone is helpful are linear immunoglobulin A (IgA) dermatosis, subcorneal pustular dermatosis, leukocytoclastic vasculitis, and a variety of rarer eruptions in which neutrophils predominate, including some forms of cutaneous lupus erythematosus.

Clinical Use

Leprosy (multidrug regimens)
Prophylaxis of malaria, treatment of chloroquine-resistant malaria (in combination with pyrimethamine)
Prophylaxis of toxoplasmosis (in combination with pyrimethamine)
Prophylaxis (monotherapy) and treatment (in combination with trimethoprim) of Pneumocystis jirovecii pneumonia
Dermatitis herpetiformis and related skin disorders

부작용

Although usually well tolerated at standard doses, gastrointestinal upsets, anorexia, headaches, dizziness and insomnia may occur. Less frequent reactions include skin rashes, exfoliative dermatitis, photosensitivity, peripheral neuropathy (usually in non-leprosy patients), tinnitus, blurred vision, psychoses, hepatitis, nephrotic syndrome, systemic lupus erythematosus and generalized lymphadenopathy.
The term ‘dapsone syndrome’ is applied to a skin rash and fever occurring 2–8 weeks after starting therapy and sometimes accompanied by lymphadenopathy, hepatomegaly, jaundice and/or mononucleosis.
Blood disorders include anemia, methemoglobinemia, sulfhemoglobinemia, hemolysis (notably in patients with glucose- 6-phosphate dehydrogenase deficiency), mononucleosis, leukopenia and, rarely, agranulocytosis. Severe anemia should be treated before patients receive dapsone.
The incidence of adverse reactions declined in the 1960s but reappeared around 1982 when multidrug therapy was introduced, and may represent an unexplained interaction with rifampicin.

Safety Profile

Poison by ingestion, intraperitoneal, and subcutaneous routes. Human systemic effects by ingestion: agranulocytosis, change in tubules and other kidney changes, cyanosis, effect on joints, hemolysis with or without anemia, jaundice, methemoglobinemiacarboxyhemoglobinemia, retinal changes, somnolence. Experimental reproductive effects. Can cause hepatitis, dermatitis, and neuritis. Questionable carcinogen with experimental carcinogenic and neoplastigenic data. Human mutation data reported. Used in leprosy treatment and veterinary medicine. When heated to decomposition it emits very toxic fumes of NOx and SOx. See also SULFONATES.

4,4'-설포닐디아닐린 준비 용품 및 원자재

원자재

준비 용품


4,4'-설포닐디아닐린 공급 업체

글로벌( 325)공급 업체
공급자 전화 팩스 이메일 국가 제품 수 이점
Shenzhen Sendi Biotechnology Co.Ltd.
0755-23311925 18102838259
0755-23311925 Abel@chembj.com CHINA 3203 55
Henan DaKen Chemical CO.,LTD.
+86-371-55531817
info@dakenchem.com CHINA 21957 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 20676 55
Mainchem Co., Ltd.
+86-0592-6210733
+86-0592-6210733 sales@mainchem.com CHINA 32452 55
Xiamen AmoyChem Co., Ltd
+86 (0)592-605 1114
sales@amoychem.com CHINA 6374 58
Yancheng Green Chemicals Co.,Ltd
86-515-87883661
86-515-87883652 sales@greenchem-china.com CHINA 349 58
Hebei Chisure Biotechnology Co., Ltd.
+8613292890173
0311 66567340 luna@speedgainpharma.com CHINA 1019 58
career henan chemical co
+86-371-86658258
sales@coreychem.com CHINA 25796 58
Hebei Huanhao Biotechnology Co., Ltd.
86-0311-83975816 whatsapp +8618034554576
86-0311-83975816 grace@hbhuanhao.com CHINA 704 58
Chemwill Asia Co.,Ltd.
86-21-51086038
86-21-51861608 chemwill_asia@126.com;sales@chemwill.com;chemwill@hotmail.com;chemwill@gmail.com CHINA 23957 58

4,4'-설포닐디아닐린 관련 검색:

Copyright 2019 © ChemicalBook. All rights reserved